Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA TrialRoy S. Herbst, Masahiro Tsuboi, Margarita Majem et al.|Journal of Clinical Oncology|2023Cited by 386
Osimertinib after Chemoradiotherapy in Stage III <i>EGFR</i> -Mutated NSCLCShun Lu, Suresh S. Ramalingam, Terufumi Kato et al.|New England Journal of Medicine|2024Cited by 291